Adjuvant Therapy for Gallbladder Carcinoma: The Mayo Clinic Experience

Gold, Douglas G.; Miller, Robert C.; Haddock, Michael G.; Gunderson, Leonard L.; Quevedo, Fernando; Donohue, John H.; Bhatia, Sumita; Nagorney, David M.

doi:10.1016/j.ijrobp.2008.10.052

Cited by 129 publications

(90 citation statements)

References 27 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study of SEER database made a prediction model which predicts that adjuvant radiation therapy provides a survival benefit in node-positive or !T2 GB cancer [13]. Some previous studies on concurrent chemoradiation therapy for GB cancer have been reported [9,14,15]. However, there is still no established standard regimen of adjuvant chemotherapy for GB cancer [16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Adjuvant chemoradiation therapy in gallbladder cancer

Cho

Kim

Park

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: Gallbladder cancer is a relatively uncommon gastrointestinal malgnancy. Indications for adjuvant chemoradiation therapy after surgical resection have not yet been determined. We aimed this study to elucidate the effectiveness of adjuvant chemoradiation therapy according to TNM stage for gallbladder cancer. Methods: Between March 2001 and March 2009, 100 patients with gallbladder cancer underwent surgical resection. We divided the patients according to TNM stage, and subdivided further according to whether adjuvant chemoradiation therapy was added or not. The clinicopathologic factors, recurrence and survival were retrospectively analyzed. Results: Patients with gallbladder cancer at T2N0M0, T2N1M0, T3N0M0, and T3N1M0 stages were enrolled in this study. Among the four stages, the two lymph node-negative stages (T2N0M0 and T3N0M0) did not show any gain in survival by adding adjuvant chemoradiation therapy. Conversely, the remaining lymph node-positive stages (T2N1M0 and T3N1M0) showed gain in disease-free survival, and the lymph node-positive T2 stage (T2N1M0) showed gain in disease-specific survival. In patients with lymph node-positive T2/T3 GB cancers, adjuvant chemoradiation therapy was an independent prognostic factor for survival. Conclusions: Adjuvant chemoradiation therapy is recommended for lymph node-positive T2/T3 gallbladder cancer following surgical resection.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant chemoradiation therapy in gallbladder cancer

Cho

Kim

Park

et al. 2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…However, patients who received adjuvant CRT had more advanced disease, and after adjusting for T and N category and histopathologic diagnosis, adjuvant CRT was a significant predictor of improved survival in multivariate Cox analysis (hazard ratio 0.3, P o 0.001). 18 Cho et al also retrospectively studied the role of adjuvant CRT in 100 patients with T2-T3 and node-positive disease in South Korea. In this study, node-positive patients receiving adjuvant CRT were found to have benefits in DFS and cause-specific survival, and CRT remained an independent prognostic factor for survival on multivariate analysis.…”

Section: Adjuvant Crt Therapymentioning

confidence: 99%

WITHDRAWN: Defining the Role of Adjuvant Therapy: Cholangiocarcinoma and Gallbladder Cancer

Williams

Majithia

Wang

et al. 2014

Seminars in Arthroplasty

View full text Add to dashboard Cite

“…In contrast, systemic disease, with or without concomitant locoregional recurrence, occurred in 85% of patients with gallbladder cancer, 75% with periampullary cancer and 41% with hilar cholangiocarcinoma [10,11] . Because of poor survival after curative resection due to frequent local relapse and distant metastases [9][10][11]36] , the role of adjuvant therapy has been widely explored [16,32,38,[41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56] .…”

Section: Therapeutic Managementmentioning

confidence: 99%

Adjuvant treatment in biliary tract cancer: To treat or not to treat?

Cereda

Belli

Reni

2012

WJG

View full text Add to dashboard Cite

Biliary tract cancer is a rare malignant tumor. There is limited knowledge about biology and natural history of this disease and considerable uncertainty remains regarding its optimal diagnostic and therapeutic management. The role of adjuvant therapy is object of debate and controversy. Although resection is identified as the most effective and the only potentially curative treatment, there is no consensus on the impact of adjuvant chemotherapy and/or radiotherapy on the high incidence of disease recurrence and on survival. This is mainly due to the rarity of this disease and the consequent difficulty in performing randomized trials. The only two prospectively controlled trials concluded that adjuvant chemotherapy did not improve survival. Most of the retrospective trials, which had limited sample size and included heterogeneous patients population and non-standardized therapies, suggested a marginal benefit of chemoradiotherapy in reducing locoregional recurrence and an uncertain impact on survival. Welldesigned multi-institutional randomized trials are necessary to clarify the role of adjuvant therapy. Two ongoing phase Ⅲ trials may provide relevant information.

show abstract

Adjuvant Therapy for Gallbladder Carcinoma: The Mayo Clinic Experience

Cited by 129 publications

References 27 publications

Adjuvant chemoradiation therapy in gallbladder cancer

Adjuvant chemoradiation therapy in gallbladder cancer

WITHDRAWN: Defining the Role of Adjuvant Therapy: Cholangiocarcinoma and Gallbladder Cancer

Adjuvant treatment in biliary tract cancer: To treat or not to treat?

Contact Info

Product

Resources

About